The Ser/Thr Kinase MAP4K4 Controls Pro-Metastatic Cell Functions

Dimitra Tripolitsioti1, Michael A Grotzer1,2 and Martin Baumgartner7

1Department of Oncology, Children's Research Center, University Children's Hospital Zürich, August-Forel Strasse 1, CH-8008 Zürich, Switzerland
2Department of Oncology, University Children's Hospital Zürich, Steinwiesstrasse 75, CH-8032 Zürich, Switzerland

Corresponding author: Martin Baumgartner, Department of Oncology, University Children's Hospital Zürich, Children's Research Center, August-Forel Strasse 1, CH-8008 Zürich, Switzerland; Tel: +41 44 634 88 20; Fax: +41 44 634 88 59; E-mail: Martin.Baumgartner@kispi.uzh.ch

Received date: December 20, 2016; Accepted date: January 31, 2017; Published date: February 03, 2017

Abstract

The search for novel targeted therapies for major human conditions such as diabetes, cardiovascular diseases and cancer is a slow and costly process. Progress is often hampered by poor drug efficaciousness in the patients, low selectivity/specificity of the compounds and cellular evasion mechanism that are rather common in anti-cancer therapies. This is particularly true also for compounds inhibiting kinases, which in theory are optimal targets thanks to their druggable enzymatic activity. Novel targeting strategies are needed to reduce side effects and treatment failure caused by non-specific drug function and target resistance, respectively. An ideal compound will repress the relevant kinase effector function, while leaving kinase functions that are not disease-relevant unaltered. To achieve function-specific inhibition, the molecular mechanism of the drug target that governs the pathological process, must be identified.

The Ser/Thr kinase MAP4K4 is implicated in inflammatory and metabolic disorders and cancer progression. In this review, we describe the molecular effector functions of MAP4K4 that exert those activities and how they have been identified and characterized both in invertebrate organisms and mammals. We discuss how the modulation of the cellular cytoskeleton by MAP4K4 may be connected to pathological conditions such as aberrant angiogenesis and cancer metastasis, and we describe the molecular mechanisms that are so far known to be mechanistically involved in these processes.

Keywords: MAP4K4; Cytoskeleton; Cancer metastasis; Cancer progression

Introduction

MAP4K4 (Mitogen activated protein kinase kinase kinase kinase 4, also known as Hepatocyte progenitor kinase-like/germinal center kinase-like kinase (HGK) and Nck-interacting kinase (NIK)) is a serine/threonine protein kinase and member of the human STE20 family kinases; it was first identified as a kinase interactor of the adaptor protein Nck in mice [1] and short time later the human orthologue was cloned as well [2]. The MAP4K4 gene is located on chromosome 2 at position q11.2 and encodes from 33 exons a protein containing 1288 amino acids. Structurally, MAP4K4 contains an N-terminal kinase domain, a coiled-coil domain, a C-terminal hydrophobic leucine-rich citron homology domain (CNH) and two putative caspase cleavage sites [3,4]. An interdomain connecting the kinase and the CNH domain is involved in protein-protein interactions but is structurally and functionally only poorly understood. Alternative splicing results in five isoforms that display differences in interdomain composition, while kinase and CNH domain are 100% homologous. MAP4K4 is well conserved and orthologues are found across species. Genetic interference and gene expression analyses have implicated MAP4K4 activity in a plethora of cellular functions relevant for physiological and pathophysiological processes, including organ development, systemic inflammation, metabolic disorders and cancer.

The astounding bandwidth of these functions, which are further detailed below, indicates the interaction of MAP4K4 with a range of structurally and functionally different effectors. Surprisingly however, only a few interactors have so far been described, highlighting the still incomplete understanding we currently have of how MAP4K4 exerts its functions. Most of the so far identified MAP4K4 interactors are functionally associated with the modulation of the actin and microtubule cytoskeletons. It is thus tempting to speculate that MAP4K4 modulates cell behavior via targeting the underlying cytoskeleton dynamics. In this review, we will particularly focus on the role of MAP4K4 in cancer and cancer progression and discuss how MAP4K4-controlled cytoskeleton dynamics could initiate and sustain the complex morphodynamic processes associated with cancer initiation and progression.

Signaling Through MAP4K4

Since its discovery in the late nineties, only relatively few details on the regulation of MAP4K4 activity and its substrates could be revealed. This is all the more surprising, considering the wealth of its implications in development, metabolic disorders and cancer. Convincing evidence in different mammalian and fly cell systems revealed MAP4K4 functions closely associated with the tumor necrosis factor alpha (TNFa)-induced c-Jun N-terminal kinase (JNK) signaling pathway [1,2,5,6]. TNFa-induced JNK activation by MAP4K4 involves signal transmission through the kinases TAK1, MKK4 and MKK7 [2]. Interestingly, MAP4K4 not only mediates TNFa signaling but also promotes TNFa expression [2], while TNFa can also cause the specific increase in MAP4K4 expression via the transcription factors c-Jun and ATF2 [7,8]. On the one hand, this positive feed-back regulation of TNFa signaling through MAP4K4 is likely involved in physiological cell functions during development and for tissue homeostasis. On the
other hand, aberrant TNFα signaling through MAP4K4 was also linked to pathophysiological processes using genetic ablation and pharmacological inhibition approaches.

These processes include insulin sensitivity [8], systemic inflammation [9], pathogen-dependent oncogenic progression [10,11] and vascular inflammation and atherosclerosis [12]. In addition to the TNFα-receptor, growth factors (GF) such as PDGF or EGF activate MAP4K4 through receptor tyrosine kinases (RTKs) [2] and trigger the phosphorylation and activation of the MAP4K4 substrates sodium-proton exchanger [1] (NHE1) [13], ezrin, radixin, moesin (ERM) family proteins [14] and actin-related protein [2] (Arp2) [15]. Genetic studies in C. elegans identified an interaction between the worm ortholog of MAP4K4–MIG-15–and integrin/PAT3 [16].

Whether integrin receptor engagement could activate MAP4K4 signaling analogous to the TNFα receptor or the RTKs described above is currently not known. However, compelling evidence indicates that MAP4K4 decreases surface availability of active integrins [17], for example by inactivating integrins via moesin phosphorylation, which concomitantly competes with talin for integrin binding [18], or by accelerating their endosomal trafficking [19].

Still in the context of integrin signaling, MAP4K4 was found to be phosphorylated by the focal adhesion kinase Pyk2 [20], which is regulated by intracellular calcium levels and activated by G-protein-coupled receptors [21].

Although not directly activated by transforming growth factor β/bone morphogenetic protein (TGFβ/BMP), MAP4K4 as well as the closely-related TNK and MINK promote inhibitory phosphorylation of Thr312 in the TGFβ/BMP effector R-Smads1/2/3/5/8 [22].

Somewhat counterintuitively, MAP4K4 along with its relatives MAP4K1-6, were recently also found to phosphorylate and activate the kinase Large Tumor Suppressor 1/2 (LAT1/2) under conditions of serum starvation [23], which inactivates Yes-associated protein 1 (YAP1) in the evolutionary conserved Hippo pathway. Hippo pathway activation and phosphorylation-dependent cytosolic retention of the YAP transcriptional regulator is tumor suppressive, as it prevents pro-proliferative and anti-apoptotic YAP signaling [24].

Together, a still incomplete picture begun to emerge, where MAP4K4 activation in membrane proximal, upstream compartments occurs in response to TNFα receptor, RTKs, and—possibly—also G-protein-coupled receptor ligation, to trigger JNK and Hippo pathway activation, sodium-proton exchange, actin polymerization and plasma membrane remodeling (Figure 1).

From Insulin Resistance to Cell Motility: The Panoply of MAP4K4 Control of Physiological Processes

Glucose up-take and insulin function

The pathological failure of cells to respond to insulin with glucose up-take and metabolization is referred to as insulin resistance. It causes blood glucose levels to raise above the normal range, is associated with obesity, hypertension and cardiovascular diseases and eventually results in type 2 diabetes [25,26]. Causative mechanisms for insulin resistance include impaired insulin receptor (IR) signaling and the concomitantly deficient ability to restrict hepatic glucose output, as well as reduced uptake of glucose into muscle and adipose tissue through the glucose transporter GLUT4. An siRNA screen identified MAP4K4 as a negative regulator of GLUT4 control of glucose metabolism in adipocytes that impairs GLUT4 expression and function 8. Inflammation-associated TNFα regulates insulin action negatively by repressing signaling downstream of the insulin receptor and by preventing GLUT4 translocation. Depletion of MAP4K4 ameliorates systemic inflammation in a murine model by reducing TNFα expression in macrophages [9]. This led to the hypothesis that MAP4K4 could also mediate the detrimental effects in glucose metabolizing cells exposed to systemic TNFα. Indeed, silencing MAP4K4 reverted TNFα-dependent IRS2 depletion and insulin repression in beta cells [27], and it restored peroxisome proliferator-activated receptor gamma (PPARgamma) expression by de-repression of mTORC for a normalized glucose and lipid metabolism in adipocytes [28]. Consistently, microRNA 30d repression of MAP4K4 expression in pancreatic cells protected beta-cells against TNFα-induced suppression of both insulin transcription and secretion, further confirming MAP4K4 targeting as a beneficial strategy for diabetes prevention [29].

MAP4K4 has also been suggested as a potential biomarker in non-obese type 2 diabetes, since decreased MAP4K4 expression rates attributed to increased methylation of the MAP4K4 promoter were observed in non-obese type 2 diabetes patients compared to healthy subjects [30]. Further in vivo studies demonstrated that MAP4K4 deletion led to decreased fasting blood glucose concentrations and...
enhanced insulin signaling in adipose tissue and liver [31], and that MAP4K4 mediates hyperinsulinemia in chronic obesity by promoting islet hypertrophy and insulin secretion from pancreatic cells [32]. MAP4K4 is also implicated in vascular inflammation and the formation of atherosclerotic plaques, where it enhances TNFα-induced vascular endothelial permeability, macrophage recruitment and adhesion [12].

These clear indications of the functional significance of MAP4K4 in inflammation-associated pathologies call for the use of therapeutics specifically targeting MAP4K4. However, the discovery of conditional MAP4K4 deficiency in T cells causing systemic inflammation and insulin resistance in mice sound a note of caution [33]. In T cells, MAP4K4 directly phosphorylates TNF receptor-associated factor 2 (TRAF2), leading to its degradation, repression of IL-6 production and the concomitant suppression of Th17 cell differentiation, which triggers an insulin resistant phenotype. Another study revealed that MAP4K4 expression in CD4+ T-cells restricts lung inflammation in response to the environmental pollutant ozone-oxidized black carbon (oBC), which is characterized by increased numbers of macrophages, lymphocytes, neutrophils, cytokine secretion and bronchoalveolar lavage fluid accumulation (BALF) [34]. Finally, mice lacking endothelial MAP4K4 displayed lymphatic defects such as dilated lymphatic capillaries, insufficient lymphatic valves, and impaired lymphatic flow [35], suggesting that beneficial effects of MAP4K4 targeting in the atherosclerotic blood vasculature may have negative impact on lymphatic drainage. Thus, careful future studies will be required to assess the cell-type specific functions of MAP4K4 and their role in metabolic and inflammatory diseases.

Development and Differentiation

The Drosophila ortholog of MAP4K4 – misshapen (MSN) – was initially identified as shape control gene in the Drosophila eye [36]. Subsequent studies implicated it upstream of Drosophila JNK to control dorsal closure during late embryogenesis [5]. In mammals, MAP4K4 plays a critical role in stimulating migration of presomitic mesodermal cells away from the Primitive Streak (PS) and in promoting the differentiation of presomitic mesoderm into somites [37]. Its absence causes embryonic lethality between days 9.5 and 10.5. MAP4K4 is also involved in the control of epithelial to mesenchymal transition (EMT) during gastrulation, where it along with the p38-interacting protein (p38IP) activates p38 to downregulated E-cadherin expression [38]. E-cadherin down-regulation contributes to the mesenchymal phenotype, which is prerequisite for cells to move away from the primitive streak. Interestingly, the above signaling cascade functions independently from the well characterized EMT-associated pathway that involves FGF and the Snail transcription factor, and suggests an alternative route requiring MAP4K4 activation of p38 [38].

TGFβ/BMP signaling, which is involved in early development, axis formation and patterning [39], is negatively regulated by MAP4K4 and prevented from exerting its correct function during Drosophila imaginal disk formation [22]. Although speculative, MAP4K4 could thus be involved in spatio-temporal fine tuning of TGFβ/BMP signaling during development. It is also conceivable, that alterations in this regulation in the context of aberrant MAP4K4 activation could result in developmental defects in the embryo and cancer initiation/progression in the adult organism. In addition to its role in the developing organism, MAP4K4 also contributes to reshaping the adult organism, where it restricts differentiation of myoblasts into myotubes [40] or in enteroblasts, where it controls differentiation by phosphorylation of the Hippo pathway core component LATS1/2 and concomitant degradation of the transcriptional regulators YAP/TAZ [41].

Axon Navigation and Neurite Outgrowth

Axonal migration during development is a complex process that controls the correct orientation and connection of axons. MAP4K4 is involved in axonal navigation and neuronal pathfinding with the first evidence being identified in Drosophila with the identification of Msn/MAP4K4 control of photoreceptor pathfinding [42]. Shortly after, the genetic interaction of MIG-15/MAP4K4 and the integrin Ina-1 was found to be required for proper axon navigation in C. elegans [16]. While MIG-15 appears to be dispensable for lamellipodia and filopodia dynamics during growth cone outgrowth and cell migration, it is required for proper directional control of neuronal outgrowth [43]. Comparative time lapse imaging of growth cone dynamics revealed that MIG-15 mechanistically interacts with the ezrin/radixin/moesin ortholog ERM-1 at the rear end of the growth cone, to restrict lateral protrusions and to maintain directional migration [44]. In mammalian cells, MAP4K4 was identified in a high-throughput screen for regulators of neurite outgrowth. In contrast to its neuro-promoting functions during development, MAP4K4 depletion in cerebellar granule neurons significantly increased the length of regenerating neurites, suggesting that MAP4K4 in mammals restricts neuronal outgrowth [45]. This finding was confirmed by an unrelated study using a militarinone-inspired 4-hydroxy-2-pyridone inhibitor targeting MAP4K4, which resulted in neurogenesis [46]. MAP4K4 inhibition is also a reported target of kenpaullone, an inhibitor of Amyotrophic Lateral Sclerosis (ALS) [47]. Consistent with a potentially destructive function of MAP4K4 for neuronal integrity, kenpaullone improved the survival of human motor neurons derived either from mouse embryonic stem cells or from ALS-patient-induced pluripotent stem cells. Interestingly, kenpaullone efficiency was partially attributed to its inhibition of the MAP4K4-TAK1-MKK4-JNK-c-Jun cell death signaling cascade. Together, these somewhat conflicting results from developing organisms and mature neurons corroborate the relevance of proper MAP4K4 function for neuronal development and integrity. However, future research will be necessary to reconcile the stabilizing functions of MAP4K4 during neuronal development with its destructive signaling in mature neurons. It will also be of particular interest to explore whether kenpaullone could be used to treat brain cancers with increased MAP4K4 expression such as glioblastoma [3,48] and medulloblastoma [49].

MAP4K4 is Overexpressed in Solid Tumors

A comparative analysis of healthy tissues with lines of the National Cancer Institute tumor panel revealed striking up-regulation of MAP4K4 in latter, with glioblastoma cancer cell lines displaying the highest upregulation in MAP4K4 expression levels [3]. Since then, a number of studies listed below have noted increased expression and/or altered function of MAP4K4 in tumors.

Brain tumors

Transcription analyses in glioblastoma multiforme cell lines and primary samples revealed that EGFRvIII, a constitutively activated EGFR mutant, leads to specific upregulation of a group of genes including MAP4K4 [48]. Also in a glioblastoma model, MAP4K4 was
found to interact with the focal adhesion-related kinase Pyk2 and to cooperate with it for glioblastoma cell migration [20]. MAP4K4 expression is also markedly higher in pediatric Medulloblastoma, particularly in the SHH and Group 4 subgroups, compared to healthy cerebellum tissue, and promotes tumor cell migration and invasion downstream of the hepatocyte growth factor receptor c-Met [49].

Pancreatic ductal adenocarcinoma

MAP4K4 is overexpressed in 46% of stage II Pancreatic Ductal Adenocarcinoma (PDA) primary samples, with particular overexpression detected in the neoplastic epithelium compared to the PDA stroma [50]. Furthermore, multivariate statistical analyses in PDA samples revealed the association of MAP4K4 expression with poor overall and recurrence-free survival, recommending it as a prognostic marker for patients with stage II PDA [51].

Colorectal cancer

MAP4K4 and four additional genes (LYN, SDCBP, DKK1, and MID1) consist a five-gene signature in colorectal cancer highly correlated with poor overall survival of the patients. In addition, increased MAP4K4 mRNA expression per se closely correlates with metastasis, tumor invasion and decreased overall patient survival [52].

Lung adenocarcinoma

Adenocarcinoma is the most common histological subtype of lung cancer and accounts for almost half of all lung cancers. Elevated MAP4K4 expression is closely associated with lung adenocarcinoma progression and is an independent prognostic factor predicting poor overall survival [53].

Hepatocellular carcinoma (HCC)

MAP4K4 expression is increased in Hepatocellular carcinoma (HCC) specimens compared to adjacent non-tumor liver tissues, and its upregulation correlates positively with tumor size, tumor grade and intrahepatic metastasis. Consistently, high MAP4K4 expression is an independent predictor of poor prognosis in HCC patients [54].

Gastric cancer

Gastric cancer is the second most common cause of cancer-associated mortality worldwide. In more than 2/3 of gastric cancer patient samples increased MAP4K4 expression levels were detected compared to adjacent non-tumor regions [55].

Ovarian cancer

In contrast to all other solid tumors investigated, MAP4K4 expression levels correlate negatively with tumor load in a murine model of ovarian cancer. In this study, non-transformed ovarian epithelial cells were compared to their spontaneously transformed counterparts using genome-wide transcriptome analysis. Alterations in the gene expression profile were then correlated with the profiles of four different human ovarian cancer types [56].

microRNA regulation of MAP4K4 expression in cancer

microRNAs (miRNAs) are endogenous, small noncoding RNAs, with a length of approximately [19-24] nucleotides that negatively regulate gene expression by base pairing complementary sites on the 3'-untranslated region (3'-UTR) of target messenger RNAs [57]. Several MAP4K4-targeting miRNAs were found repressed in tumors, leading thus to increased levels of MAP4K4 expression. These include Let7a in Kaposi sarcoma, miR-194 in CRC [58] and HCC [59] and miR-622 in CRC [60].

MAP4K4 Controls Pro-Metastatic Functions in Cancer Progression

Increased expression levels of MAP4K4 at mRNA or protein levels have been correlated with tumor aggressiveness and reduced patient survival. But what are the molecular events controlled by MAP4K4 that trigger or maintain the transformed cellular phenotype and promote metastatic disease? Despite research efforts ongoing for close to 20 years, this question still remains incompletely answered. Improved gene interference strategies and the development of small compound inhibitors of MAP4K4 have simplified the identification of effector pathways and putative molecular interactors. Nevertheless, the effector molecules of MAP4K4 and how their interaction with altered MAP4K4 expression or function is coupled to the biological outcome, remains enigmatic in most instances. Key biological functions controlled by MAP4K4 are reviewed in the following section.

Tumor cell growth

Ras-transformation of NIH3T3 fibroblasts enables these cells to grow independent of adhesion to a rigid matrix (anchorage independent growth). Ablation of MAP4K4 function in such NIH3T3 fibroblasts by the overexpression of a kinase-inactive MAP4K4 mutant completely abrogated anchorage independence, suggesting that MAP4K4 contributes an essential function to anchorage-independent survival and growth [3]. Knock-down of MAP4K4 caused cell cycle arrest and apoptosis in HCCs [54] and in gastric cancer cells (GCCs) [55]. Cell cycle arrest and apoptosis after MAP4K4 knock-down was accompanied by the repression of JNK, NF kappa B, and toll-like receptor (TLR) signaling in GCCs [54, 55]. Whether impaired HCC and GCC growth after MAP4K4 ablation is indeed the consequence of repressed JNK, NF-kappa B and TLR signaling, or rather mediated by an alternative route in these cancer cell lines is not clear. However, since MAP4K4 ablation does not cause growth arrest and apoptosis in all cancer cell lines, the susceptibility factor in the sensitive ones remains to be determined.

Cell migration and invasion

Early studies in Drosophila and C. elegans pointed towards cell shape and migration control as hallmark functions of MAP4K4 signaling [5,36,61]. Since disturbed morphodynamics and cell migration control are intimately associated with the cancerous phenotype, studies in cancer cell lines soon confirmed the pro-migratory function of MAP4K4 [3,62]. MAP4K4 implications in migration control in the context of cell transformation was also shown in macrophages infected with the protozoan parasite Theileria annulata, where parasite-induced TNFα secretion by the host cell activates MAP4K4 in an autocrine manner, to drive migration and invasion of the host cell [11]. In an inflammatory context as well, MAP4K4 promotes Kaposi Herpes virus-infected cell migration by controlling the expression of genes responsible for motility and invasiveness such as COX-2, MMP-7 and MMP-13. In HCC, MAP4K4 depletion markedly reduced cancer cell migration both in vitro and in vivo.
vivo, reduced cell adhesion to extracellular matrix (ECM) proteins and impaired the expression of NF-xb and the Matrix Metalloproteases 2 and 9 [54-63]. In the malignant pediatric brain tumor medulloblastoma, MAP4K4 is overexpressed and mediates migration and invasion downstream of HGF and EGF [49], whereas in adult glioblastoma cells, MAP4K4 was found to interact with Pyk2, a member of the focal adhesion kinase family, and to be required for migration and invasion [20]. Molecular mechanisms linking MAP4K4 activity to pro-metastatic functions Figure 2.

Cytoskeleton dynamics at the cell front during migration is controlled among many other factors by local pH gradients. The sodium/proton (Na+/H+) exchanger 1 (NHE1) causes spatially-restricted H+ efflux at the leading edge of cells [66]. In addition to its exchanger activity, NHE1 also acts as a membrane anchor for the cytoskeleton and an assembly point for signaling molecules [67-69]. MAP4K4 binds to and phosphorylates the C-terminus of NHE1 and causes its activation, which increases the intracellular pH in proximity of the plasma membrane [13]. NHE1 is involved in cell migration control [70-72] and associated with metastatic functions in cancer cells [73-75]. GF control of this central regulator of cortical cell functions through MAP4K4 may contribute to local remodeling of the cytoskeleton [76,77] and enable the formation of invasive membrane protrusions. Not surprisingly, targeting NHE1 has emerged as a potential strategy in tumor treatment [78].

Another possible function of MAP4K4 in cell migration and invasion control is its activity towards the actin-related protein 2 (Arp2) subunit of the Arp2/3 complex. Arp2 phosphorylation by MAP4K4 increased the actin nucleation activity of the Arp2/3 complex in vitro and in EGF-stimulated cells, demonstrating that MAP4K4 can couple growth factor (GF) signaling to F-actin polymerization [15]. MAP4K4 accumulates at the leading edge of cells migrating on/in either 2D or 3D matrix [3,11,14,49,79]. Thus, MAP4K4-driven F-actin polymerization at the leading edge combined with its activity towards focal adhesions makes it a prime candidate for GF control of the membrane protrusions at the leading edge of cells that drive invasive cancer cell motility. Indeed, depletion of MAP4K4 in medulloblastoma cells infiltrating collagen I matrix caused a defect in protrusion formation and completely abrogated GF-induced cancer cell invasion [49].

**Therapeutics Targeting MAP4K4 Functions**

The broad implication of MAP4K4 in human disease conditions including metabolic and inflammatory disorders as well as cancer have incited efforts in the pharmaceutical industry to develop a specific small compound inhibitor. Genentech applied two separate fragment-based lead discovery approaches, which identified pyridopyrimidine scaffold-based compound 29 (C29) [80] and C35 [40]. Starting from a micromolar pyrrolotriazine fragment hit, Genentech developed a series of MAP4K4 inhibitors with single digit nanomolar IC50s by utilizing crystal structures and molecular modeling. Calculated properties were used to guide the optimization of solubility and in vitro stability, yielding compounds with excellent biochemical potencies, ligand efficiencies and favorable in vivo bioavailability in mice. However, with many small compound kinase inhibitors, moderate kinase selectivity was observed and the closely related kinase Misshapen-like kinase 1 (MINK1) and TRAF2- and Nck-interacting kinase (TNIK) were also effectively inhibited by both compounds. C35 was found to be even less specific as it also blocked activities of Cdk1, Flt3, KDR, KHS1, and Mink1 by more than 75% [40]. Nevertheless, C29 was found to be a valuable tool in in vivo studies but its applicability suffered from the shortcoming that it was poorly tolerated when dosed repeatedly [80]. Its capability to permeate into the CNS was suspected to cause the poor tolerability. Medical chemistry efforts were therefore undertaken to reduce penetration of C29 into the CNS. The resulting GNE-495 reduced brain exposure while maintaining potent activity...
and good kinase selectivity, and recapitulated the phenotypes of MAP4K4 inducible knockout mice [81]. In a search for pharmacologically active compounds targeting pathological angiogenesis, the GNE-220—yet another MAP4K4 inhibitor from Genentech—was identified. This compound prevented MAP4K4-dependent talin replacement by C-terminally phosphorylated moesin from the intracellular domain of integrin β1, and reversed membrane retraction defects in endothelial cells associated with pathological angiogenesis [18].

A virtual screening approach using the crystal structure of the MAP4K4 kinase domain was employed by Pfizer, and the compound PF-6260933 with excellent selectivity was developed [82]. However, similar to the Genentech compounds, PF-6260933 also inactivated TNK and MINK. PF-6260933 was used in a study investigating MAP4K4 function in vascular inflammation and atherosclerosis. It phenocopied the MAP4K4 knock-down and ameliorated plaque development in a murine model for atherosclerosis [12].

MAP4K4 is highly expressed in the brain tissue and its implications in neurodegenerative disorders have been addressed in the context of a search for natural products with neurotrophic and/or neuroprotective activities [46]. One such bioactive compound - militarinone-A - was identified as metabolite of a Cordycept fungus. Militarinone-A analogs, as metabolite of a Cordycept fungus. Militarinone-A analogs, were generated and as their protein targets were not known, they were analyzed for kinase selectivity. To evaluate the neurotrophic activity of those Militarinone-A analogs, they were subjected to phenotypic screening in the human neuroblastoma cell line SH-SY5Y. Compound 11e enhanced neurite outgrowth and inhibited MAP4K4 kinase activity in vitro, making it a suitable starting compound for future studies related to neurological disorders and – possibly – also MAP4K4-dependent brain tumors [46].

Concluding Remarks

The amazing diversity of MAP4K4 pathological function in different human conditions calls for a more general reflection on the biological processes it is involved with, and how they are associated with a specific disease condition. In this context, the regulation of the actin cytoskeleton is a good example, as it not only enables cellular morphodynamics but also spatially controlled signaling, surface receptor trafficking and turnover and endocytic up-take, to name only a few. MAP4K4 modulates the remodeling of the F-actin cytoskeleton in response to growth factors (GF) such as HGF, EGF and PDGF or the pro-inflammatory cytokine TNFα, both by directly controlling polymerization dynamics as well as signaling mediators associated with cytoskeleton control. The tripartite mechanism control of F-actin remodeling by MAP4K4 through pH regulation [13], actin polymerization and branching [15] and F-actin anchoring [14], strongly argues for MAP4K4 effectively translating growth factor (GF) signaling into cytoskeleton alterations affecting not only the overall morphology of the cell, but also how signals are transmitted inside the cell and how surface receptors are made available. Such alterations also support the disease conditions MAP4K4 was found associated with, in particular in pathological angiogenesis and cancer metastasis. On the one hand, it will thus be of importance to further dissect the downstream effector mechanisms of MAP4K4 specific to the condition, in order to more specifically target its function in this process. On the other hand, the signaling functions of MAP4K4 should not be observed isolated, but rather in the context of its broader impact on the cytoskeleton. Consequently, inflammatory signaling triggered by TNFα and mediated by MAP4K4, should thus also be investigated under the angle of the effects MAP4K4 may have on cytoskeleton modulation. An example for such context-dependent, global modulation of cell function was observed in a host-pathogen model, where parasite-dependent, TNFα-induced MAP4K4 signaling in the host cells bifurcates into JNK expression and activation on the one hand and ER protein-associated control of lamellipodium dynamics and invasive motility on the other hand [11]. Through its activity at different levels of cell function, specific targeting of its context-dependent actions may thus emerge as a therapy specifically tailored to the disease-causing activity, and hence reduce non-desired side-effects of treatment.

Acknowledgments

This work was supported by grants of the Swiss National Science foundation (SNF_3100A4-144090/1) to M.B. and of the Childhood Cancer Research Foundation Switzerland to M.A.G.

References


